PDGFRA and neoplasm: We used a breast cancer cell line that does not express CXCR4 to determine whether NT21MP inhibits the EMT process through the CXCR4/PDGFRα signaling pathway and demonstrated that NT21MP targeted CXCR4, inhibits EMT, and inhibits tumor progression.